C2N Diagnostics Brings Home Positive Results for Alzheimer ’s Test

C2N Diagnostics’s detection test for Alzheimer’s disease is showing off some strong data coming out of the 12th Annual Clinical Trials in Alzheimer’s Disease conference. The St. Louis-based company said results from a study show the Aptus-Aβ test strongly predicts the presence of brain amyloidosis in a diverse population. C2N Diagnostics said its blood-based in vitro diagnostic is being developed to predict amyloid PET scan results. It combines into a ratio, the concentration of amyloid beta (Aβ) isoforms Aβ42 and Aβ40 in human plasma, as measured by mass spectrometry. Amyloid PET scans accurately detect amyloid plaques – one of the hallmarks of Alzheimer’s disease – and are used in the workup and management of people with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive decline. In the study, C2N applied the Aptus-Aβ blood test to 415 samples previously collected from individuals enrolled at six different locations across the United States. “We partnered with a number of [Alzheimer’s disease Research Centers] and we wound up getting access to biobank samples,” Joel Braunstein, MD, CEO of C2N, told MD+DI. “These are samples that individuals have consented to provide their b...
Source: MDDI - Category: Medical Devices Authors: Tags: IVD Source Type: news

Related Links:

In Reply The Letter to the Editor by Montero-Odasso and colleagues addresses noncognitive manifestations of Alzheimer disease (AD). Their letter discusses a recent article from the Mayo Clinic. Using positron emission tomography biomarkers of amyloidosis (A) and tauopathy (T), the Mayo study examined the age- and sex-specific prevalence of 3 biologically defined entities: amyloidosis (A+) regardless of tau status, A+T −, and A+T+. We compared the age and sex specific prevalence of these 3 biomarker-defined entities with 3 clinical syndromes commonly associated with AD: clinically defined probable AD using the McKhann...
Source: JAMA Neurology - Category: Neurology Source Type: research
Nonphysiologic overexpression of amyloid-β (Aβ) precursor protein in common transgenic Aβ mouse models of Alzheimer disease likely hampers their translational potential. The novel AppNL-G-F mouse incorporates a mutated knock-in, potentially presenting an improved model of Alzheimer disease for Aβ-targeting treatment trials. We aimed to establish serial small-animal PET of amyloidosis and neuroinflammation in AppNL-G-F mice as a tool for therapy monitoring. Methods: AppNL-G-F mice (20 homozygous and 21 heterogeneous) and 12 age-matched wild-type mice were investigated longitudinally from 2.5 to 10 mo of ...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Basic Source Type: research
Researchers at the University of Turku have discovered new changes in blood samples associated with Alzheimer’s disease. A new study was conducted on disease-discordant Finnish twin pairs: one sibling suffering from Alzheimer's disease and the other being cognitively healthy. The researchers used the latest genome-wide methods to examine the twins' blood samples for any disease-related differences in epigenetic marks which are sensitive to changes in environmental factors. These differences between the siblings were discovered in multiple different genomic regions. Development of the late-onset form of Al...
Source: MDDI - Category: Medical Devices Authors: Tags: R & D Source Type: news
In conclusion, in the absence of obesity, visceral adipose tissue possesses a pronounced anti-inflammatory phenotype during aging which is further enhanced by exercise. Methods of Inducing Cellular Damage are Rarely Relevant to Aging, and the Details Matter https://www.fightaging.org/archives/2019/08/methods-of-inducing-cellular-damage-are-rarely-relevant-to-aging-and-the-details-matter/ One of the major challenges in aging research is determining whether or not models of cellular or organismal damage and its consequences are in any way relevant to the natural processes of aging. One can hit a brick with...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
DISCUSSION: Our results encourage an independent validation cohort study to confirm the indication that the plasma Aβ1-40/Aβ1-42 ratio, assessed via Simoa, may improve future standard of care and clinical trial design. PMID: 31113759 [PubMed - as supplied by publisher]
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
53Aim: Immunmodulatory treatment with the PPAR agonist Pioglitazone shows heterogeneous results in Alzheimer`s disease (AD). We aimed to apply longitudinal in-vivo PET monitoring combined with terminal cognitive assessment to investigate PET as a tool for longitudinal monitoring of treatment effects and to establish efficacy determinants. Methods: PS2APP (TG) mice and C57Bl/6 (WT) mice were randomly stratified in Pioglitazone (N=13 TG, N=8 WT) and placebo treatment (N=10 TG, N=7 WT) at the age of 8 months. Therapy was conducted for 5 months (mo). All mice received amyloid-PET (Aβ-PET) scans (F-18-Florbetaben) at basel...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Brain Imaging Council YIA Symposium Source Type: research
Conclusions: 11C-PIB PET/MR may be valuable in the noninvasive diagnosis of CA. Further study with a larger cohort of patients would be needed to confirm it.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Cardiovascular YIA Symposium Source Type: research
DiscussionOur results encourage an independent validation cohort study to confirm the indication that the plasma Aβ1–40/Aβ1–42 ratio, assessed via Simoa, may improve future standard of care and clinical trial design.
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - Category: Geriatrics Source Type: research
In this study, we report the age-associated differences between fetal MSC (fMSC) populations and MSCs isolated from elderly donors with respect to their transcriptomes. We successfully reprogrammed fMSCs (55 days post conception) and adult MSC (aMSC; 60-74 years) to iPSCs and, subsequently, generated the corresponding iMSCs. In addition, iMSCs were also derived from ESCs. The iMSCs were similar although not identical to primary MSCs. We unraveled a putative rejuvenation and aging gene expression signature. We show that iMSCs irrespective of donor age and cell type re-acquired a similar secretome to that of th...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Conclusions: Our results demonstrate that the presence and extent of cSS are associated with reduced CSF ß-amyloid 42 levels. Further studies are needed to investigate the underlying mechanisms of this association. Introduction Cerebral amyloid angiopathy (CAA)—characterized by the deposition of ß-amyloid in the walls of leptomeningeal vessels—is a common cerebral small vessel disease and a major cause of intracerebral hemorrhage in the elderly (1–3). Furthermore, it has become evident that CAA is associated with cognitive impairment (4). Specifically, it has been shown that CAA patien...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
More News: Alzheimer's | Amyloidosis | Brain | Clinical Trials | Conferences | Genetics | Laboratory Medicine | Medical Devices | Neurology | PET Scan | Study | USA Health